Client Pear Therapeutics Uses SPAC Merger in Path to Nasdaq

Pear Therapeutics, a prescription digital therapeutics company, has announced it will be using a SPAC merger to bring it public, valued at 1.6 billion. The company plans to focus most of their energy on their robust pipeline of CNS therapies. But don’t expect Pear to stop at neuroscience—other potential assets range from oncology to cardiology.

As a client, Pear has and continues to partner with Westwood & Wilshire to place key individuals in clinical development. These searches were led by Gerard Danishek, a Director within the Digital Health Practice at Westwood & Wilshire. Gerard is currently leading the searches for both Vice President of R&D and Global Clinical Lead – Substance Use Disorders.

Congratulations to President and CEO, Corey McCann, as well as the rest of the Pear team on this exciting milestone.